Presentation is loading. Please wait.

Presentation is loading. Please wait.

Does Chlorambucil Add to Obinutuzumab in the Treatment of the Unfit CLL Patient? NO Richard R. Furman, MD CLL Research Center.

Published byMonica Stevens Modified over 9 years ago

Similar presentations

Presentation on theme: "Does Chlorambucil Add to Obinutuzumab in the Treatment of the Unfit CLL Patient? NO Richard R. Furman, MD CLL Research Center."— Presentation transcript:

1 Does Chlorambucil Add to Obinutuzumab in the Treatment of the Unfit CLL Patient?
NO Richard R. Furman, MD CLL Research Center

2 Obinutuzumab Type II humanized IgG1 Glycoengineered to have:
Enhanced ADCC Modified elbow to increase PCD MOA No induction of migration to lipid rafts Stimulate direct cell death associated with: actin reorganization homotypic adhesion lysosomal mediated cell death

3 CLL 11: Obinutuzumab Pivotal Design
Arm 1: chlorambucil x 6 cycles R A N CLL Patients: Untreated Unfit for chemo CIRS >6 CrCl mL/min D Stage 1 O M Arm 2: obinutuzumab + chlorambucil x 6 cycles I Z A Stage 2 T I Arm 3: rituximab + chlorambucil x 6 cycles O N

4 CLL 11: G-Clb vs. Clb Progression Free Survival
Goede V. NEJM 2014; 370:1101

5 CLL 11: G-Clb vs. Clb Overall Survival
Goede V. NEJM 2014; 370:1101

6 R-Clb vs Clb + G-Clb vs Clb
R-Clb + Clb G-Clb + Clb Goede V. NEJM 2014; 370:1101

7 Problem Lack single agent data as a comparator in untreated CLL patients Cannot rule out additive or synergistic effects Increased antibody dose provides greater efficacy Reduced tumor bulk provides greater efficacy

8 Obinutuzumab: Response by Tumor Burden in Relapsed / Refractory CLL (GAUGUIN)
Cartron G. Blood. 2014; 124:2196.

9 CLL11: Progression Free Survival vs. Time to Next Treatment
PFS: TTT:

10 Problem PFS for: clb = 11.1 months clb + rituximab = 16.3 months
Lack single agent data as a comparator in untreated CLL patients Cannot rule out additive or synergistic effects Increased antibody dose provides greater efficacy Reduced tumor bulk provides greater efficacy PFS for: clb = 11.1 months clb + rituximab = 16.3 months clb + obinutuzumab = 26.7 months TTT for: clb = 14.8 months Clb + obinutuzmab = NR

11 Obinutuzumab in Untreated CLL: GAGE Trial
GA mg Days 1, 8, 15 of Cycle 1 Day 1 of Cycle 28, every 3 weeks GA mg Previously untreated CLL (n=80) All patients required treatment by IWCLL criteria Randomized 1:1 Stratification factors: Tumor burden at baseline (high or low) Presence (high) or absence (low) of at least one nodal mass ≥ 5 cm in the baseline CT scan Rai Stage at baseline (I/II or III/IV)

12 GAGE Trial: Progression Free and Overall Survival
1000 mg (N=41) 2000 mg (N=39) Event, n (%) 13 (32) 10 (26) Progression 12 9 Death 1 Progression free survival (months) Median (95% CI) 21 (13, 28) 20 (19, NE) 18-month PFS, % 59% 83% P value = 0.07 Overall survival (months), median Not reached Flynn JM. ASCO 2014

13 Adverse Event in >5% of Patients
G-Clb % Clb % Neutropenia 41 18 Nausea 13 25 Anemia 12 10 Thrombocytopenia 15 8 Diarrhea 11 Fatigue 7 Pyrexia Constipation Asthenia Cough Headache Vomiting 5 Nasopharyngitis Bronchitis Anorexia 3 Pneumonia Dyspnea 2 Abdominal pain Rash Insomnia 4 Arthralgia Back pain Leukopenia Goede V. NEJM 2014; 370:1101

14 Adverse Event in >5% of Patients
G-Clb % Clb % Neutropenia 41 18 Nausea 13 25 Anemia 12 10 Thrombocytopenia 15 8 Diarrhea 11 Fatigue 7 Pyrexia Constipation Asthenia Cough Headache Vomiting 5 Nasopharyngitis Bronchitis Anorexia 3 Pneumonia Dyspnea 2 Abdominal pain Rash Insomnia 4 Arthralgia Back pain Leukopenia Goede V. NEJM 2014; 370:1101

15 CLL 11 vs GAGE CLL 11: PFS: clb = 11.1 months
clb + rituximab = 16.3 months clb + obinutuzumab = 26.7 months TTT: clb = 14.8 monts clb + obinutuzumab = NR GAGE: PFS: obinutuzumab 1000 mg = 21 months obinutuzumab 2000 mg = 20 months TTT: ?

16 Risk of t-MN with FC vs F in Untreated CLL: E2997
Therapy FC F TOTAL N enrolled 141 137 278 t-MN 9 4 13 Additional Therapy: yes no 2 7 3 1 Crude Incidence 6.4% 2.9% 4.7% Cumulative Incidence (at 7 yrs) 8.2% 4.6% Smith, M Blood; 118: 3525

17 Second Cancers: F vs. Clb CALGB 9011
509 patients 27 epithelial cancers Fludarabine: 9 chlorambucil: 11 F + C: 7

18 Summary: Does Obinutuzumab Need Chlorambucil
Chlorambucil may aid obinutuzumab by reducing bulk. Unnecessary with higher doses of antibody Single agent obinutuzumab approaches combinatin PFS Greater toxicities with chlorambucil Have not looked at long-term toxicity of alkylator use

Download ppt "Does Chlorambucil Add to Obinutuzumab in the Treatment of the Unfit CLL Patient? NO Richard R. Furman, MD CLL Research Center."

Similar presentations

Palumbo A et al. Proc ASH 2013;Abstract 536.

Palumbo A et al. Proc ASH 2013;Abstract 536.
What is the Optimal Approach to CLL, BR vs. FCR/FR?

What is the Optimal Approach to CLL, BR vs. FCR/FR?
Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma
Brown JR et al. Proc ASH 2013;Abstract 523.

Brown JR et al. Proc ASH 2013;Abstract 523.
Goede V et al. Proc ASCO 2013;Abstract 7004.

Goede V et al. Proc ASCO 2013;Abstract 7004.
New Data for Old Drugs in CLL Kanti R. Rai MD Joel Finkelstein Cancer Foundation Professor of Medicine Hofstra North Shore-LIJ School of Medicine Hempstead,

New Data for Old Drugs in CLL Kanti R. Rai MD Joel Finkelstein Cancer Foundation Professor of Medicine Hofstra North Shore-LIJ School of Medicine Hempstead,
1Coiffier B et al. Proc ASH 2010;Abstract 114.

1Coiffier B et al. Proc ASH 2010;Abstract 114.
Roberts AW et al. Proc ASH 2014;Abstract 325.

Roberts AW et al. Proc ASH 2014;Abstract 325.
Lymphoma & Myeloma 2014 October 24, 2014 Obinutuzumab: Analysis of it’s Pivotal Data Myron S. Czuczman, MD Chief, Lymphoma/Myeloma Section Head, Lymphoma.

Lymphoma & Myeloma 2014 October 24, 2014 Obinutuzumab: Analysis of it’s Pivotal Data Myron S. Czuczman, MD Chief, Lymphoma/Myeloma Section Head, Lymphoma.
Presented by Martin H. Cohen, M.D. at the 27 July 2004 meeting of the Oncologic Drugs Advisory Committee.

Presented by Martin H. Cohen, M.D. at the 27 July 2004 meeting of the Oncologic Drugs Advisory Committee.
Agne Paner, MD Assistant professor of Medicine RUSH University Medical Center.

Agne Paner, MD Assistant professor of Medicine RUSH University Medical Center.
Efficacy of Denileukin Diftitox Retreatment in Patients with Cutaneous T-Cell Lymphoma Who Relapsed After Initial Response 1 Identification of an Active,

Efficacy of Denileukin Diftitox Retreatment in Patients with Cutaneous T-Cell Lymphoma Who Relapsed After Initial Response 1 Identification of an Active,
Bosch F et al. Proc ASH 2014;Abstract 3345.

Bosch F et al. Proc ASH 2014;Abstract 3345.
Eastern cooperative oncology group E1496: ECOG and CALGB Cyclophosphamide/Fludarabine (CF) with or without Maintenance Rituximab (MR) in Advanced Indolent.

Eastern cooperative oncology group E1496: ECOG and CALGB Cyclophosphamide/Fludarabine (CF) with or without Maintenance Rituximab (MR) in Advanced Indolent.
Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy in first-line human epidermal growth factor receptor.

Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy in first-line human epidermal growth factor receptor.
Interim Results of an International, Multicenter, Phase 2 Study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory.

Interim Results of an International, Multicenter, Phase 2 Study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory.
Frontline Therapy with Brentuximab Vedotin Combined with ABVD or AVD in Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma Younes A et al. Proc.

Frontline Therapy with Brentuximab Vedotin Combined with ABVD or AVD in Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma Younes A et al. Proc.
Final Analysis of a Phase 2 Study of Lenalidomide and Rituximab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) 1 Lenalidomide.

Final Analysis of a Phase 2 Study of Lenalidomide and Rituximab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) 1 Lenalidomide.
1 A Randomized, Multi-Center Phase III Trial of Irinotecan in Combination with Three Different Methods of Administration of Fluoropyrimidine with Celecoxib.

1 A Randomized, Multi-Center Phase III Trial of Irinotecan in Combination with Three Different Methods of Administration of Fluoropyrimidine with Celecoxib.
FUSION  Design  Objectives –SVR ≥ 20% compared with historical control of 25%, 97% power –Difference of SVR > 20% between the 2 groups, 82% power SOF.

FUSION  Design  Objectives –SVR ≥ 20% compared with historical control of 25%, 97% power –Difference of SVR > 20% between the 2 groups, 82% power SOF.

Similar presentations

Ads by Google